Zobrazeno 1 - 10
of 714
pro vyhledávání: '"Towfic F"'
Autor:
Stokes ME; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Wenzl K; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Huang CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Ortiz M; Informatics and Predictive Sciences, Bristol Myers Squibb, Seville, Spain., Hsu CC; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Maurer MJ; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Stong N; Informatics and Predictive Sciences, Bristol Myers Squibb, Summit, NJ, USA., Nakayama Y; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Wu L; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Chiu H; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Polonskaia A; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Danziger SA; BMS at the time the study was conducted, Amazon, Seattle, WA, USA., Towfic F; BMS at the time the study was conducted, Prometheus Biosciences, San Diego, CA, USA., Parker J; LifeEDIT Therapeutics, Research Triangle Park, Durham, NC, USA., King RL; Division of Hematopathology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, USA., Link BK; Division of Hematology, Oncology, Blood and Marrow Transplant, University of Iowa, Iowa City, IA, USA., Slager SL; Division of Hematology, Mayo Clinic, Rochester, MN, USA.; Department of Quantitative Health Sciences, Mayo Clinic, Rochester, MN, USA., Sarangi V; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Asmann YW; Department of Health Science Research, Mayo Clinic, Jacksonville, FL, USA., Novak JP; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Sudhindra A; Clinical Research and Development, Bristol Myers Squibb, Summit, NJ, USA., Ansell SM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Habermann TM; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Hagner PR; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA., Nowakowski GS; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Cerhan JR; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Novak AJ; Division of Hematology, Mayo Clinic, Rochester, MN, USA., Gandhi AK; Translational Medicine Hematology, Bristol Myers Squibb, Summit, NJ, USA. anita.gandhi@bms.com.
Publikováno v:
Nature communications [Nat Commun] 2024 Aug 08; Vol. 15 (1), pp. 6790. Date of Electronic Publication: 2024 Aug 08.
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
K zobrazení výsledku je třeba se přihlásit.
Autor:
Stong N; Predictive Sciences, Bristol Myers Squibb, Summit, NJ., Ortiz-Estévez M; Predictive Sciences, BMS Center for Innovation and Translational Research Europe (CITRE), A Bristol Myers Squibb Company, Seville, Spain., Towfic F; Predictive Sciences, Bristol Myers Squibb, San Diego, CA., Samur M; Dana-Farber Cancer Institute, Boston, MA.; Harvard TH Chan School of Public Health, Boston, MA., Agarwal A; Medical Affairs, Bristol Myers Squibb, Summit, NJ., Corre J; Unit of Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Flynt E; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Munshi N; Dana-Farber Cancer Institute, Boston, MA.; VA Boston Healthcare System, West Roxbury, MA.; Harvard Medical School, Boston, MA., Avet-Loiseau H; Unit of Genomics in Myeloma, Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Thakurta A; Translational Medicine, Bristol Myers Squibb, Summit, NJ.
Publikováno v:
Blood [Blood] 2023 Mar 30; Vol. 141 (13), pp. 1574-1583.
Autor:
Ansari-Pour N; Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; National Institute for Health and Care Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Samur M; Dana-Farber Cancer Institute, Boston, MA.; Harvard T.H. Chan School of Public Health, Boston, MA., Flynt E; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Gooding S; Medical Research Council Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; National Institute for Health and Care Research Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom., Towfic F; Bristol Myers Squibb, Summit, NJ., Stong N; Predictive Sciences, Bristol Myers Squibb, Summit, NJ., Estevez MO; Predictive Sciences, BMS Center for Innovation and Translational Research Europe, A Bristol Myers Squibb Company, Sevilla, Spain., Mavrommatis K; Computational Genomics, Bristol Myers Squibb, San Francisco, CA., Walker B; Melvin and Bren Simon Comprehensive Cancer Center, Division of Hematology Oncology, Indiana University, Indianapolis, IN., Morgan G; Perlmutter Cancer Center, NYU Langone Medical Center, New York, NY., Munshi N; Dana-Farber Cancer Institute, Boston, MA.; VA Boston Healthcare System, West Roxbury, MA.; Harvard Medical School, Boston, MA., Avet-Loiseau H; Institut Universitaire du Cancer de Toulouse-Oncopole, Toulouse, France., Thakurta A; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom.; Bristol Myers Squibb, Summit, NJ.; Nuffield Department of Orthopaedics Rheumatology and Musculoskeletal Disease, University of Oxford, Oxford, United Kingdom.
Publikováno v:
Blood [Blood] 2023 Feb 09; Vol. 141 (6), pp. 620-633.
Autor:
Gandhi, A.K., Hagner, P.R., Risueño, A., Parker, J.S., Ren, Y., Maurer, M.J., Pourdehnad, M., Djebbari, A., Wang, M., Nowakowski, G.S., Towfic, F., Trotter, M.W.B., Lee, C.-W., Wei, X., Fontanillo, C., Drew, C.P., Couto, S., Cerhan, J.R.
Diffuse large B-cell lymphoma (DLBCL) is a heterogeneous disease, commonly described by cell-of-origin (COO) molecular subtypes. We sought to identify novel patient subgroups through an unsupervised analysis of a large public dataset of gene expressi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0ad4a5b3b1b2183dc4ca7f5685cf34c2
Autor:
Gooding S; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom., Ansari-Pour N; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Kazeroun M; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Karagoz K; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Polonskaia A; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Salazar M; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom., Fitzsimons E; Department of Haematology, Cancer Institute, University College London, United Kingdom., Sirinukunwattana K; Department of Engineering, University of Oxford, Oxford, United Kingdom., Chavda S; Department of Haematology, Cancer Institute, University College London, United Kingdom., Ortiz Estevez M; Bristol Myers Squibb Center for Innovation and Translational Research Europe, Sevilla, Spain., Towfic F; Bristol Myers Squibb, San Diego, CA., Flynt E; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Pierceall W; Translational Medicine, Bristol Myers Squibb, Summit, NJ., Royston D; Nuffield Department of Cellular and Laboratory Sciences, University of Oxford, Oxford, United Kingdom., Yong K; Department of Haematology, Cancer Institute, University College London, United Kingdom., Ramasamy K; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom., Vyas P; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom., Thakurta A; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom.; Nuffield Department of Orthopedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom.
Publikováno v:
Blood [Blood] 2022 Oct 20; Vol. 140 (16), pp. 1816-1821.
Autor:
Hagner PR; Bristol Myers Squibb, Summit, New Jersey., Chiu H; Bristol Myers Squibb, Summit, New Jersey., Chopra VS; Genentech, San Francisco, California., Colombo M; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Patel N; Loxo Oncology, San Francisco, California., Estevez MO; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Waldman MF; Bristol Myers Squibb, Summit, New Jersey., Loos R; Celgene Corporation, a Bristol Myers Squibb Company, Seville, Spain., Towfic F; Bristol Myers Squibb, Summit, New Jersey., Gandhi AK; Bristol Myers Squibb, Summit, New Jersey.
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2022 Aug 02; Vol. 28 (15), pp. 3367-3377.
Deletions of chromosome 17p (del17p) that span the TP53 gene are associated with poor outcome in multiple myeloma (MM), but the prognostic value of del17p cancer clonal fraction (CCF) remains unclear. We applied uniform cytogenetic assessments in a l
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=od______2127::d36368ae36d6e80e96732ea625096df6
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3000466
https://pergamos.lib.uoa.gr/uoa/dl/object/uoadl:3000466
Autor:
Karagoz K; Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States., Stokes M; Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States., Ortiz-Estévez M; Bristol Myers Squibb Center for Innovation and Translational Research Europe, Sevilla, Spain., Towfic F; Bristol Myers Squibb, San Diego, CA, United States., Flynt E; Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States., Gooding S; MRC Molecular Haematology Unit, Weatherall Institute of Molecular Medicine, University of Oxford, Oxford, United Kingdom.; Department of Haematology, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.; NIHR Oxford Biomedical Research Centre, University of Oxford, Oxford, United Kingdom.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom., Pierceall W; Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States., Thakurta A; Translational Medicine, Bristol Myers Squibb, Summit, NJ, United States.; Oxford Centre for Translational Myeloma Research, University of Oxford, Oxford, United Kingdom.
Publikováno v:
Frontiers in genetics [Front Genet] 2022 Feb 09; Vol. 13, pp. 831779. Date of Electronic Publication: 2022 Feb 09 (Print Publication: 2022).
Autor:
Ortiz-Estévez M; BMS Center for Innovation and Translational Research Europe (CITRE), A Bristol Myers Squibb Company, Sevilla, Spain., Towfic F; Bristol Myers Squibb, San Diego, CA, USA., Flynt E; Bristol Myers Squibb, 181 Passaic Ave, Summit, NJ, 07901, USA., Stong N; Bristol Myers Squibb, 181 Passaic Ave, Summit, NJ, 07901, USA., Jang IS; Bristol Myers Squibb, San Diego, CA, USA., Wang K; Bristol Myers Squibb, San Diego, CA, USA., Trotter MWB; BMS Center for Innovation and Translational Research Europe (CITRE), A Bristol Myers Squibb Company, Sevilla, Spain., Thakurta A; Bristol Myers Squibb, 181 Passaic Ave, Summit, NJ, 07901, USA. anjan.thakurta@bms.com.
Publikováno v:
BMC medical genomics [BMC Med Genomics] 2021 Dec 18; Vol. 14 (1), pp. 295. Date of Electronic Publication: 2021 Dec 18.